ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1229

Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Abstract Number: 1098

Does Cancer Masquerade as Sarcoidosis?
Abstract Number: 0991

Does Diet Affect Gout Risk Differently Among Genetically Predisposed Women?: Prospective Female Cohort Study Findings over 34 Years
Abstract Number: 0626

Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
Abstract Number: 0902

Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
Abstract Number: 1903

Does Limited Stair Climbing Lead to Poor Future Health? The Relationship Between Short-term Trajectories of Stair Climbing Frequency and Incident Slow Gait Speed over 1 and 2 Years in Adults with Knee Osteoarthritis
Abstract Number: 0864

Does Obesity Affect Disease Activity Outcomes in Systemic Lupus Erythematosus?
Abstract Number: 0672

Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Abstract Number: 1918

Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Abstract Number: 0724

Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Abstract Number: 0364

Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Routine Care – 2-year Clinical and MRI Outcomes and Predictors of Successful Tapering
Abstract Number: 1483

Down-regulation of Hematopoietic Progenitor Kinase 1 by Aberrant Epigenetic Alterations in T Follicular Helper Cells Accounts for Excessive Immunity in Systemic Lupus Erythematosus
Abstract Number: 1222

Drug Response Is Associated with Changes in Specific MicroRNAs in Patients with Rheumatoid Arthritis
Abstract Number: 0911

Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Abstract Number: 0516

Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].